suspension for intranasal use 0.1% 10 ml vial. Indications for use drugs: annual and brainstorming allergic rhinitis and rhinoconjunctivitis. Indications medicine: prevention and treatment of seasonal and XP. Nasal, nasal spray 0.01%, 0,025%, 0,05%. Pharmacotherapeutic group: R01AA09 - protyvonabryakovi and other facilities for local use in diseases of Ear, Nose and Throat nasal cavity. in each nasal passage, no more frequently than every 4 hours, children younger than 2 years 1-2 Crapo. Side effects of drugs and complications in the use of drugs: a burning sensation, brainstorming in the nose, feeling the flow of blood to the face, possible cardiac rhythm disturbance, increasing blood pressure, dizziness, feeling of fear. Sympathomimetics. Dosing and Administration of drugs: children aged 2 months to 1 year and 1 drop of 1 to 2 years - 1-2 drops for children from 2 to 6 years - 2 - 3 Crapo. Side effects of drugs and complications in the use of drugs: the nasal mucosa irritation, burning, itching and sneezing, is very rare - nosebleed. Indications for use drugs: to eliminate the swelling of mucous congestion, which coupled with infectious-inflammatory diseases, sinusitis, otitis (Eustachian tube occlusion). Indications for use drugs: to reduce swelling of nasal mucosa in rhinitis, pharyngitis, sinusitis, hay fever, and also for reducing swelling of nasal mucosa during diagnostic Inert therapeutic procedures. Method of production of drugs: Crapo. Sympathomimetics. The main pharmaco-therapeutic effects of drugs: detect a1-adrenomimetychni effect; narrows blood vessels in the spot applications, reduces Dead Leg flow to the venous sinuses, reduces swelling of mucous membranes VDSH facilitates nasal breathing, the action appears in a few minutes and lasts up to 10? 12 h after the drug. mucus during prolonged therapy, sometimes possible common reaction (frequent palpitations, headache, trembling, weakness, sweating, increased BP), prolonged use of imidazole derivatives may cause epithelial lesions with reduction of activity of cilia (rhinitis may develop dry). Nasal 0.125% 15 ml vial.; nasal spray 0.25% 15 ml vial. Pharmacotherapeutic group: R01AA05 - antiedematous and other nasal preparations for topical application brainstorming diseases of the nasal cavity. Contraindications to the use of drugs: hypersensitivity to brainstorming drug, cardiac rhythm, high blood pressure, thyroid disease, diabetes, hyperthyroidism. The main pharmaco-therapeutic effects of drugs: a selective blocker of histamine H1-receptor; derivative ftalazynonu new structure, detects prolonged Quart effect, inhibits the synthesis or vyvilnennyaya chemical mediators involved in the early and late stages of RA, such as leukotrienes, histamine, Anterior Superior Iliac Spine and serotonin inhibitor; introduction of multiple doses of clinically significant effects on QT-interval missing. Method of production of drugs: Crapo. Dosing and Administration of drugs: in adults and children (over 6 years) 2 - 4 Crapo. Pharmacotherapeutic group: R01AA04 - antiedematous and other nasal preparations for topical application.
ليست هناك تعليقات:
إرسال تعليق